Molbio Diagnostics IPO Reaches 1.22x Subscription on Day 2

The initial public offering of Molbio Diagnostics gains momentum on its second bidding day, drawing steady investor interest and a positive grey market premium.

Overview

MUMBAI — The initial public offering (IPO) of point-of-care molecular diagnostics firm Molbio Diagnostics Limited progressed into its second day of bidding on August 11, 2026, registering an overall subscription rate of 1.22 times. The public issue, valued at ₹939.70 crore, has attracted active participation across retail and institutional segments as market watchers track shifting grey market trends.

The public issue is structured within a price band of ₹768 to ₹807 per equity share, with a designated lot size of 18 shares. The offering comprises a fresh issue worth ₹200 crore alongside an offer for sale (OFS) of ₹739.70 crore by existing shareholders and promoter entities. The subscription window remains open until August 12, 2026, before finalizing share allotments.

Subscription Status and Grey Market Trends

According to exchange data and market tracking reports, the Molbio Diagnostics IPO witnessed an acceleration in bidding velocity on Day 2. The grey market premium (GMP) for the counter hovered around 17%, reflecting expectations of a positive listing debut when shares are slated to list on the National Stock Exchange (NSE) and the Bombay Stock Exchange (BSE) on August 17, 2026.

Market analysts note that institutional participation has stabilized following robust anchor book commitments finalized prior to the public opening. Retail individual investors (RIIs) and non-institutional investors (NIIs) continue to evaluate the company's valuation metrics against industry benchmarks.

Use of Proceeds and Business Fundamentals

According to official regulatory filings and the red herring prospectus (RHP), net proceeds generated from the fresh issue component will be deployed toward key capital expenditure objectives. Specifically, the firm intends to allocate funds toward building advanced research and development (R&D) facilities, establishing a Centre of Excellence, and procuring state-of-the-art plant and machinery for its manufacturing units located in Goa and Visakhapatnam.

Specializing in portable, battery-operated real-time PCR testing infrastructure through its flagship Truenat platform, Molbio Diagnostics plays an essential role in decentralizing infectious disease detection across emerging healthcare markets.

Official Sources Section

Details regarding the issue size, price band, timeline, and subscription metrics are sourced directly from official filings and exchange data published by the Bombay Stock Exchange (BSE), the National Stock Exchange (NSE), and issue registrar KFin Technologies.

"According to officials, the public issue timeline proceeds as scheduled, with the bidding window closing on August 12, 2026, and share allotment finalization expected on August 13, 2026."

Why It Matters

For prospective investors and healthcare sector observers, the Molbio Diagnostics IPO serves as a key indicator of market appetite for indigenous medical technology companies. Evaluating subscription trends and grey market movements helps retail participants determine appropriate capital allocation strategies amidst evolving macroeconomic conditions.

Key Facts at a Glance

• Issue Size: ₹939.70 crore (comprising a ₹200 crore fresh issue and a ₹739.70 crore OFS).

• Price Band: ₹768 to ₹807 per equity share.

• Lot Size: 18 shares (Minimum retail investment of ₹14,526 at the upper band).

• Listing Date: August 17, 2026, on the BSE and NSE.

• Registrar: KFin Technologies Limited.

Frequently Asked Questions

1. What is the current subscription status of the Molbio Diagnostics IPO?

On its second day of bidding, the IPO reached an overall subscription rate of 1.22 times, supported by steady retail and institutional interest.

2. What is the price band for the Molbio Diagnostics IPO?

The price band is fixed between ₹768 and ₹807 per equity share, with a minimum retail lot size of 18 shares.

3. When does the Molbio Diagnostics IPO close for bidding?

The subscription window closes on August 12, 2026, followed by the basis of allotment finalization on August 13, 2026.

4. Where can investors check official allotment status?

Investors can verify their allotment status directly through the registrar portal managed by KFin Technologies or via the BSE website.

Source: Bombay Stock Exchange (BSE), National Stock Exchange (NSE), and KFin Technologies.